You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage III non-small cell lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Beijing

Recruiting
  • NSCLC
    • Beijing, China
      Yuyan Wang
    Oct 10, 2023

    Stage III NSCLC Trial (Toripalimab, JS004, Pemetrexed)

    Not yet recruiting
    • Stage III Non-small Cell Lung Cancer
    • (no location specified)
    Jun 3, 2023

    Omitting Clinical Target Volume in Radical Treatment of

    Not yet recruiting
    • Immunotherapy
    • +3 more
    • IMRT+adjuvant immunotherapy
    • (no location specified)
    Jun 9, 2023

    NSCLC Trial in Changsha (Sugemalimab and Chemotherapy)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Sugemalimab and Chemotherapy
    • Changsha, China
      Hunan Cancer Hospital
    Jul 7, 2023

    Stage III NSCLC Trial (18F FDG PET/CT, CT scan)

    Not yet recruiting
    • Stage III Non-small Cell Lung Cancer
    • 18F FDG PET/CT
    • CT scan
    • (no location specified)
    Oct 9, 2023

    Stage III NSCLC, Surgery Trial in Guangzhou (Lorlatinib)

    Not yet recruiting
    • Stage III NSCLC
    • Surgery
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Feb 21, 2023

    Omitting Clinical Target Volume of Unresectable Stage III

    Completed
    • Stage III Non-small-cell Lung Cancer
    • The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.
    • (no location specified)
    Aug 29, 2022

    NSCLC Stage III Trial in Shanghai (standar thoracic RT dose, decreased thoracic RT dose)

    Recruiting
    • Non-small Cell Lung Cancer Stage III
    • standar thoracic RT dose
    • decreased thoracic RT dose
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
    Sep 27, 2022

    NSCLC Stage III Trial in Hefei (Envafolimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer Stage III
    • Hefei, Anhui, China
      Anhui Provincial Cancer Hospital
    Jun 8, 2022

    Stage III NSCLC, Locally Advanced, Unresectable Trial (standard Radiotherapy, Chemotherapy, Immunotherapy)

    Not yet recruiting
    • Stage III Non-small Cell Lung Cancer
    • +2 more
    • standard Radiotherapy
    • +3 more
    • (no location specified)
    Oct 20, 2023

    Blood Samples in Patients With Non-small Cell Lung Cancer

    Recruiting
    • Stage III Non-Small Cell Lung Cancer AJCC v7
    • +3 more
    • Biospecimen Collection
    • Laboratory Biomarker Analysis
    • Los Angeles, California
      USC / Norris Comprehensive Cancer Center
    Nov 18, 2022

    Unresectable Melanoma, Metastatic Melanoma, Stage III NSCLC Trial in Louisville, New York (IOV-4001)

    Recruiting
    • Unresectable Melanoma
    • +3 more
    • IOV-4001
    • Louisville, Kentucky
    • +2 more
    Nov 21, 2022

    Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer Trial in United States (device, drug, radiation, procedure)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • Stage III Non-small-cell Lung Cancer
    • Durvalumab
    • +4 more
    • Chicago, Illinois
    • +3 more
    Jan 18, 2023

    Stage III NSCLC Trial in Birmingham (Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy)

    Not yet recruiting
    • Stage III Non-small Cell Lung Cancer
    • Adaptive Radiotherapy
    • +3 more
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Aug 3, 2022

    Stage III Non-small-cell Lung Cancer Trial in Foshan, Guangzhou (other, radiation, drug)

    Recruiting
    • Stage III Non-small-cell Lung Cancer
    • Neoadjuvant therapy
    • +4 more
    • Foshan, Guangdong, China
    • +2 more
    Oct 25, 2022

    Non-small-cell Lung Cancer Patients Trial in Roma (Durvalumab, Olaparib tablet, Single-agent chemo)

    Recruiting
    • Non-small-cell Lung Cancer Patients
    • Roma, RM, Italy
      Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
    Sep 30, 2022

    Mesothelin Positive, Stage III NSCLC AJCC v7, Stage IIIA NSCLC AJCC v7 Trial in Phoenix, Jacksonville, Rochester (Anetumab

    Terminated
    Has Results
    • Mesothelin Positive
    • +4 more
    • Anetumab Ravtansine
    • +2 more
    • Phoenix, Arizona
    • +2 more
    Jan 5, 2023

    NSCLC Trial in Worldwide (Alectinib, Entrectinib, Pralsetinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • San José, Costa Rica
    • +3 more
    Aug 4, 2022

    Stage III NSCLC Trial in Moscow

    Recruiting
    • Stage III Non-small Cell Lung Cancer
      • Moscow, Russian Federation
        National Medical Research Center of Oncology. N. N. Blokhin
      Dec 1, 2021

      NSCLC Trial in Jinan (Anlotinib HCl capsule Combined With Concurrent Chemoradiotherapy)

      Terminated
      • Non-small Cell Lung Cancer
      • Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
      • Jinan, Shandong, China
        Shandong Cancer Hospital
      Feb 9, 2022

      NSCLC, Stage III Trial in Indianapolis (Signatera ctDNA test)

      Not yet recruiting
      • NSCLC, Stage III
      • Signatera ctDNA test
      • Indianapolis, Indiana
        Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
      Mar 13, 2023

      Pneumonitis, Nonsmall Cell Lung Cancer Stage III Trial in Winston-Salem (Exhaled Breath Collection, Blood sample)

      Terminated
      • Pneumonitis
      • Nonsmall Cell Lung Cancer Stage III
      • Exhaled Breath Collection
      • Blood sample
      • Winston-Salem, North Carolina
        Wake Forest Baptist Comprehensive Cancer Center
      Nov 16, 2022

      NSCLC Stage III Trial in Guangzhou (CS1001 mAb, CS1001 )

      Active, not recruiting
      • Non-Small Cell Lung Cancer Stage III
      • CS1001 monoclonal antibody
      • CS1001 placebo
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Jan 20, 2022

      Reveal Patterns of Presentation, Management and Outcome of SCLC

      Recruiting
      • Lung Cancer
        • Dammam, Saudi Arabia
        • +2 more
        Jul 25, 2022

        Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer Trial in United States (BMF-219)

        Recruiting
        • Non Small Cell Lung Cancer
        • +16 more
        • Goodyear, Arizona
        • +10 more
        Jan 24, 2023